Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ADAP
- Price
- 0.22
- Stock movement up
- +0.01 (3.40%)
- Company name
- Adaptimmune Therapeutics Plc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 56.88M
- Ent value
- 177.59M
- Price/Sales
- 0.33
- Price/Book
- 0.71
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -10.33%
- 1 year return
- -82.50%
- 3 year return
- -53.97%
- 5 year return
- -39.88%
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ADAP does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.33 |
| Price to Book | 0.71 |
| EV to Sales | 1.01 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 255.88M |
| EPS (TTM) | -0.18 |
| FCF per share (TTM) | -0.22 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 175.04M |
| Gross profit (TTM) | 166.74M |
| Operating income (TTM) | -49.26M |
| Net income (TTM) | -44.93M |
| EPS (TTM) | -0.18 |
| EPS (1y forward) | -0.47 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 95.26% |
| Operating margin (TTM) | -28.14% |
| Profit margin (TTM) | -25.67% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 116.74M |
| Net receivables | 38.61M |
| Total current assets | 244.21M |
| Goodwill | 0.00 |
| Intangible assets | 4.28M |
| Property, plant and equipment | 138.23M |
| Total assets | 317.44M |
| Accounts payable | 9.07M |
| Short/Current long term debt | 24.63M |
| Total current liabilities | 63.46M |
| Total liabilities | 237.45M |
| Shareholder's equity | 79.99M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -53.66M |
| Capital expenditures (TTM) | 2.38M |
| Free cash flow (TTM) | -56.04M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -56.17% |
| Return on Assets | -14.15% |
| Return on Invested Capital | -33.52% |
| Cash Return on Invested Capital | -41.81% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.24 |
| Daily high | 0.24 |
| Daily low | 0.20 |
| Daily Volume | 1.54M |
| All-time high | 21.12 |
| 1y analyst estimate | 2.27 |
| Beta | 2.25 |
| EPS (TTM) | -0.18 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 14 May 2025 |
Downside potential
Loading...
Downside potential data
| ADAP | S&P500 | |
| Current price drop from All-time high | -98.95% | -12.89% |
| Highest price drop | -99.07% | -56.47% |
| Date of highest drop | 31 Mar 2025 | 9 Mar 2009 |
| Avg drop from high | -76.02% | -11.07% |
| Avg time to new high | 500 days | 12 days |
| Max time to new high | 2472 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
56.88M
Marketcap category
Small-cap
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Employees
449
Website
Investor relations
-
SEC filings
CEO
Adrian Rawcliffe
Country
USA
City
Abingdon
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page